Skip to content

Simulations Plus SLP Additional Paid-In Capital

Additional Paid-In Capital at other companies

Schrodinger logo
SchrodingerSDGR
$1B+4.6%
Certara, Inc. logo
Certara, Inc.CERT
$1.26B+2.7%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$1.97B-0.5%
Personalis, Inc. logo
Personalis, Inc.PSNL
$916.12M+18.5%
NeoGenomics logo
NeoGenomicsNEO
$1.28B+3.2%
Opko Health logo
Opko HealthOPK
$3.57B+2.5%

Other financials

Income statement

See full
Revenue$24.3M+8.3%
Gross profit$16.1M+23.0%
Operating income$5.6M+108%
Net income$4.5M+47.5%
EPS (diluted)$0.22+46.7%

Balance sheet

See full
Cash & equivalents$25.7M+134%
Total debt$508.0K-36.2%
Total equity$133.8M-29.4%
Total assets$146.5M-27.3%

Cash flow

See full
Operating cash flow$6.4M+13.1%
CapEx$46.0K-30.3%
Free cash flow$6.4M+13.6%

Valuation

See full
Market cap$366.73M+5.2%
Enterprise value$341.51M+6.0%
P/S4.6×+0.2×

Profitability

See full
Gross margin62%+6.7pp
Operating margin-84.3%
Net margin-78%-87.2pp
FCF margin29.5%+14.9pp

Returns & leverage

See full
Return on equity-38.8%-42.8pp
Debt / equity0.0×
Current ratio5.5×+1.1×

Where this comes from

Reported directly by Simulations Plus in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Simulations Plus’s 10-Q, filed April 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Simulations Plus's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Simulations Plus's additional paid-in capital?
Simulations Plus (SLP) reported additional paid-in capital of $163.18M in Q4 2025.
What is the long-term trend for Simulations Plus's additional paid-in capital?
Over 2 years (2020 to 2025), Simulations Plus's additional paid-in capital has grown at a 11.4% compound annual growth rate (CAGR), from $128.53M to $159.42M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.